Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure

AIMS: Several patients with heart failure and reduced ejection fraction (HFrEF) do not receive renin–angiotensin–aldosterone system (RAAS) inhibitors at the recommended dose or at all, frequently due to actual or feared hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is an orally administered no...

Descripción completa

Detalles Bibliográficos
Autores principales: Tardif, Jean‐Claude, Rouleau, Jean, Chertow, Glenn M., Al‐Shurbaji, Ayman, Lisovskaja, Vera, Gustavson, Stephanie, Zhao, Yanli, Bouabdallaoui, Nadia, Desai, Akshay S., Chernyavskiy, Alexander, Evsina, Maria, Merkely, Béla, McMurray, John J.V., Pfeffer, Marc A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053160/
https://www.ncbi.nlm.nih.gov/pubmed/36564955
http://dx.doi.org/10.1002/ehf2.14268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053160/
https://www.ncbi.nlm.nih.gov/pubmed/36564955
http://dx.doi.org/10.1002/ehf2.14268

Ejemplares similares